INGELHEIM, Germany-Friday 29 May 2020 [ AETOS Wire ]
The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2
The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4
Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in more than 40 countries.
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung
Read more »